Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria

AIDS. 2015 Sep 24;29(15):2035-44. doi: 10.1097/QAD.0000000000000798.

Abstract

Objective: To estimate the impact and cost-effectiveness of treatment as prevention (TasP), pre-exposure prophylaxis (PrEP) and condom promotion for serodiscordant couples in Nigeria.

Design: Mathematical and cost modelling.

Methods: A deterministic model of HIV-1 transmission within a cohort of serodiscordant couples and to/from external partners was parameterized using data from Nigeria and other African settings. The impact and cost-effectiveness were estimated for condom promotion, PrEP and/or TasP, compared with a baseline where antiretroviral therapy (ART) was offered according to 2010 national guidelines (CD4 <350 cells/μl) to all HIV-positive partners. The impact was additionally compared with a baseline of current ART coverage (35% of those with CD4 <350 cells/μl). Full costs (in US $2012) of programme introduction and implementation were estimated from a provider perspective.

Results: Substantial benefits came from scaling up ART to all HIV-positive partners according to 2010 national guidelines, with additional smaller benefits of providing TasP, PrEP or condom promotion. Compared with a baseline of offering ART to all HIV-positive partners at the 2010 national guidelines, condom promotion was the most cost-effective strategy [US $1206/disability-adjusted-life-year (DALY)], the next most cost-effective intervention was to additionally give TasP to HIV-positive partners (incremental cost-effectiveness ratio US $1607/DALY), followed by additionally giving PrEP to HIV-negative partners until their HIV-positive partners initiate ART (US $7870/DALY). When impact was measured in terms of infections averted, PrEP with condom promotion prevented double the number of infections as condom promotion alone.

Conclusions: The first priority intervention for serodiscordant couples in Nigeria should be scaled up ART access for HIV-positive partners. Subsequent incremental benefits are greatest with condom promotion and TasP, followed by PrEP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-Retroviral Agents / administration & dosage
  • Anti-Retroviral Agents / economics
  • Chemoprevention / economics
  • Chemoprevention / methods
  • Cohort Studies
  • Condoms / economics
  • Condoms / statistics & numerical data
  • Cost-Benefit Analysis
  • Disease Transmission, Infectious / prevention & control*
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • HIV Infections / transmission*
  • HIV Seronegativity
  • HIV Seropositivity
  • Humans
  • Male
  • Middle Aged
  • Models, Theoretical
  • Nigeria
  • Pre-Exposure Prophylaxis / economics*
  • Pre-Exposure Prophylaxis / methods*
  • Sexual Partners*
  • Young Adult

Substances

  • Anti-Retroviral Agents